The role of IFN in the development of NAFLD and NASH

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

The role of IFN in the development of NAFLD and NASH. / Møhlenberg, Michelle; Terczynska-Dyla, Ewa; Thomsen, Karen Louise; George, Jacob; Eslam, Mohammed; Grønbæk, Henning; Hartmann, Rune.

I: Cytokine, Bind 124, 154519, 2019.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{1bd51f30a7ac4e69bbe389200992c8d7,
title = "The role of IFN in the development of NAFLD and NASH",
abstract = "Non-alcoholic fatty liver disease (NAFLD) and its progressive inflammatory form non-alcoholic steatohepatitis (NASH) are major health challenges due to a significant increase in their incidence and prevalence. While NAFLD is largely benign, the chronic liver inflammation in NASH patients may cause progression to liver cirrhosis and hepatocellular carcinoma. There is an urgent need for a better understanding of the factors, which drive the progression from NAFLD to NASH and how to use this information both to improve diagnostic and to develop new treatment strategies. Increasing evidence points to interferons (IFNs) as key players in NAFLD and particular in the progression to NASH. IFNs crucial role in disease development is supported by both genetic evidence and animal studies. In this review, we describe the involvement of both type I and type III IFNs in the development and progression of NAFLD and NASH.",
keywords = "Animal models, Humans and human genetics, Interferons (IFN) type I IFN and type III IFN, Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH)",
author = "Michelle M{\o}hlenberg and Ewa Terczynska-Dyla and Thomsen, {Karen Louise} and Jacob George and Mohammed Eslam and Henning Gr{\o}nb{\ae}k and Rune Hartmann",
year = "2019",
doi = "10.1016/j.cyto.2018.08.013",
language = "English",
volume = "124",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press",

}

RIS

TY - JOUR

T1 - The role of IFN in the development of NAFLD and NASH

AU - Møhlenberg, Michelle

AU - Terczynska-Dyla, Ewa

AU - Thomsen, Karen Louise

AU - George, Jacob

AU - Eslam, Mohammed

AU - Grønbæk, Henning

AU - Hartmann, Rune

PY - 2019

Y1 - 2019

N2 - Non-alcoholic fatty liver disease (NAFLD) and its progressive inflammatory form non-alcoholic steatohepatitis (NASH) are major health challenges due to a significant increase in their incidence and prevalence. While NAFLD is largely benign, the chronic liver inflammation in NASH patients may cause progression to liver cirrhosis and hepatocellular carcinoma. There is an urgent need for a better understanding of the factors, which drive the progression from NAFLD to NASH and how to use this information both to improve diagnostic and to develop new treatment strategies. Increasing evidence points to interferons (IFNs) as key players in NAFLD and particular in the progression to NASH. IFNs crucial role in disease development is supported by both genetic evidence and animal studies. In this review, we describe the involvement of both type I and type III IFNs in the development and progression of NAFLD and NASH.

AB - Non-alcoholic fatty liver disease (NAFLD) and its progressive inflammatory form non-alcoholic steatohepatitis (NASH) are major health challenges due to a significant increase in their incidence and prevalence. While NAFLD is largely benign, the chronic liver inflammation in NASH patients may cause progression to liver cirrhosis and hepatocellular carcinoma. There is an urgent need for a better understanding of the factors, which drive the progression from NAFLD to NASH and how to use this information both to improve diagnostic and to develop new treatment strategies. Increasing evidence points to interferons (IFNs) as key players in NAFLD and particular in the progression to NASH. IFNs crucial role in disease development is supported by both genetic evidence and animal studies. In this review, we describe the involvement of both type I and type III IFNs in the development and progression of NAFLD and NASH.

KW - Animal models

KW - Humans and human genetics

KW - Interferons (IFN) type I IFN and type III IFN

KW - Non-alcoholic fatty liver disease (NAFLD)

KW - Non-alcoholic steatohepatitis (NASH)

UR - http://www.scopus.com/inward/record.url?scp=85051740828&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2018.08.013

DO - 10.1016/j.cyto.2018.08.013

M3 - Journal article

C2 - 30139548

AN - SCOPUS:85051740828

VL - 124

JO - Cytokine

JF - Cytokine

SN - 1043-4666

M1 - 154519

ER -